Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissuePRICE, B; PYNE, N. J; HOUSLAY, M. D et al.Biochemical pharmacology. 1987, Vol 36, Num 23, pp 4047-4054, issn 0006-2952Article

Electrochemical and spectral behaviour of a new cardiotonic drug (sulmazole)BERMEJO, E; ZAPARDIEL, A; HERNANDEZ, L et al.Analytical letters. 1987, Vol 20, Num 11, pp 1867-1883, issn 0003-2719Article

Cardiac glycosides, calcium and the release of neurotransmitter from peripheral noradrenergic nervesTAN, C. M; POWIS, D. A.Naunyn-Schmiedeberg's archives of pharmacology. 1985, Vol 329, Num 1, pp 1-8, issn 0028-1298Article

Digitalis and newer inotropic agentsSOMBERG, J. C.Journal of clinical pharmacology. 1985, Vol 25, Num 7, pp 477-559, issn 0091-2700Serial Issue

Effects of K⁺ on the interaction between cardiac glycosides and Na,K-ATPaseAKERA, T; YUK-CHOW NG; ING-SHIH SHIEH et al.European journal of pharmacology. 1985, Vol 111, Num 2, pp 147-157, issn 0014-2999Article

The basic mechanism of inotropic action of digitalis glycosidesSMITH, T. W.Journal de pharmacologie. 1984, Vol 15, pp 35-51, issn 0021-793X, suppl. 1Article

Amrinone, a symposium was held on November 11, 1984 in Miami FLThe American journal of cardiology. 1985, Vol 56, Num 3, pp 26.B-42.B, issn 0002-9149Conference Proceedings

Zur Pharmakologie eines neuen Kardiosteroids, einem partialsynthetischen Derivat des Aglykons Hellebrigenin (Acrihellin) = Pharmacologie d'un nouveau cardiostéroïde, dérivé synthétique partiel de l'aglycone hellebrigenine (Acrihelline) = Pharmacology of a new cardiosteroid, a partially synthetic derivative of the aglycon hellebrigenin (Acrihellin)STROMAN, F; JAKOVLEV, V; METZENAUER, P et al.Arzneimittel-Forschung. 1984, Vol 34, Num 7, pp 769-779, issn 0004-4172Article

The new inotropic phosphodiesterase inhibitorsEL ALLAF, D; D'ORIO, V; CARLIER, J et al.Archives internationales de physiologie et de biochimie. 1984, Vol 92, Num 4, pp S69-S79, issn 0003-9799Article

Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockadeCOLLIS, M. G; KEDDIE, J. R; TORR, S. R et al.British journal of pharmacology. 1984, Vol 81, Num 2, pp 401-407, issn 0007-1188Article

Classification of positive inotropic agentsFELDMAN, A. M.Journal of the American College of Cardiology. 1993, Vol 22, Num 4, pp 1223-1227, issn 0735-1097Article

Intérêt et limites des nouveaux agents cardiologiques = New inotropic agents: interest and limitationsGROSGOGEAT, Y; KOMAJDA, M.Bulletin de l'Académie nationale de médecine. 1989, Vol 173, Num 2, pp 121-131, issn 0001-4079, 11 p.Article

The cardiac glycoside digoxin does not alter the activity of human polymorphonuclear leukocytes in vitroESPOSITO, A. L; CLARK, C. A; POIRIER, W. J et al.The Journal of infectious diseases. 1988, Vol 157, Num 5, pp 1084-1087, issn 0022-1899Article

Potentielle Kardiotonika. XII, 6-(Pyrid-4-yl)-substituierte Pyrido[2,3-d]pyrimidine = Potential cardiotonic drugs. XII, 6-(pyrid-4-yl)-substituted pyrido [2,3-d] pyrimidineHAGEN, V; KLAUSCHENZ, E; KNOLL, A et al.Pharmazie. 1991, Vol 46, Num 7, issn 0031-7144, p. 531Article

Measurement of cardioactive drugs in biological samples by HPLCFLANAGAN, R. J; BHAMRA, R. K; WALKER, S et al.Journal of liquid chromatography. 1988, Vol 11, Num 5, pp 1015-1040, issn 0148-3919Article

The vasodilatory effects of levosimendan on the human internal mammary arteryMONTES, Félix R; ECHEVERRI, Dario; BUITRAGO, Lorena et al.Anesthesia and analgesia. 2006, Vol 103, Num 5, pp 1094-1098, issn 0003-2999, 5 p.Article

Effects of pimobendan (UDCG 115) on renal function in healthy volunteersMARTIN, P; TINDALL, H; RICE, P et al.Journal of international medical research. 1992, Vol 20, Num 3, pp 267-272, issn 0300-0605Article

Use of cholestyramine in the treatment of digoxin intoxicationHENDERSON, R. P; SOLOMON, C. P.Archives of internal medicine (1960). 1988, Vol 148, Num 3, pp 745-746, issn 0003-9926Article

Classification of positive inotropic actions based on electrophysiologic characteristics : Where should calcium sensitizers be placed ?VARRO, A; PAPP, J. G.Journal of cardiovascular pharmacology. 1995, Vol 26, pp S32-S44, issn 0160-2446, SUP1Conference Paper

A simple aid to digoxin prescribingTAGGART, A. J; MCDEVITT, D. G; JOHNSTON, G. D et al.European journal of clinical pharmacology. 1987, Vol 33, Num 5, pp 441-445, issn 0031-6970Article

Lack of specificity of current anti-digoxin antibodies, and preparation of a new, specific polyclonal antibody that recognizes the carbohydrate moiety of digoxinTHONG, B; SOLDIN, S. J; LINGWOOD, C. A et al.Clinical chemistry (Baltimore, Md.). 1985, Vol 31, Num 10, pp 1625-1631, issn 0009-9147Article

Effects of hyperkalemia on the electrocardiogram of patients receiving digitalisWEIZENBERG, A; CLASS, R. N; SURAWICZ, B et al.The American journal of cardiology. 1985, Vol 55, Num 8, pp 968-973, issn 0002-9149Article

Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac diseaseBOROW, K. M; COME, P. C; NEUMANN, A et al.The American journal of cardiology. 1985, Vol 55, Num 9, pp 1204-1209, issn 0002-9149Article

Digoxin-trimethoprim interactionPETERSEN, D; KASTRUP, J; BARTRAM, R et al.Acta medica Scandinavica. 1985, Vol 217, Num 4, pp 423-427, issn 0001-6101Article

Interactions médicamenteuses avec les digitaliques = Drug interactions with digitalisANDREJAK, M.NPN médecine. 1985, Vol 5, Num 97, pp 1057-1060, issn 0248-9635Article